<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144339</url>
  </required_header>
  <id_info>
    <org_study_id>205.235</org_study_id>
    <nct_id>NCT00144339</nct_id>
  </id_info>
  <brief_title>Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to determine whether daily treatment with tiotropium
      (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of
      decline in lung function over time in patients with COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years</measure>
    <time_frame>From day 30 to 4 years</time_frame>
    <description>Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years</measure>
    <time_frame>From day 30 to 4 years</time_frame>
    <description>Rate of decline of forced expiratory volume in one second (FEV1) measured after bronchodilation. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment</measure>
    <time_frame>Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days.</time_frame>
    <description>Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment</measure>
    <time_frame>Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days</time_frame>
    <description>Rate of decline of forced expiratory volume in one second (FEV1) measured after the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years</measure>
    <time_frame>From day 30 to 4 years</time_frame>
    <description>Rate of decline of forced vital capacity (FVC) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years</measure>
    <time_frame>From day 30 to 4 years</time_frame>
    <description>Rate of decline of forced vital capacity (FVC) measured after bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years</measure>
    <time_frame>From day 30 to 4 years</time_frame>
    <description>Rate of decline of slow vital capacity (SVC) measured before the use of bronchodilators. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years</measure>
    <time_frame>From day 30 to 4 years</time_frame>
    <description>Rate of decline of slow vital capacity (SVC) measured after bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Decline of St George's Respiratory Questionnaire (SGRQ) Total Score</measure>
    <time_frame>From month 6 to 4 years</time_frame>
    <description>SGRQ total score shows the impact of COPD on patient's health status, and expressed as a percentage of impairment with scale from 0 (best health status) to 100 (worst possible status). A negative rate of decline shows decreasing SGRQ total score (or improved health) over time, while a positive value shows increasing score (or worsen health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment</measure>
    <time_frame>Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days.</time_frame>
    <description>Rate of decline of forced vital capacity (FVC) before bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment</measure>
    <time_frame>Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days</time_frame>
    <description>Rate of decline of forced vital capacity (FVC) after bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment</measure>
    <time_frame>Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days</time_frame>
    <description>Rate of decline slow vital capacity (SVC) before bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment</measure>
    <time_frame>Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days</time_frame>
    <description>Rate of decline of slow vital capacity (SVC) after bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Exacerbation</measure>
    <time_frame>From Day 1 to 4 years</time_frame>
    <description>Chronic obstructive pulmonary disease (COPD) exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient Year</measure>
    <time_frame>Day 1 to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Patients With at Least One Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</measure>
    <time_frame>Day 1 to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Exacerbation Days Per Patient Year</measure>
    <time_frame>Day 1 to 4 years</time_frame>
    <description>Number of exacerbation days normalized by treatment exposure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First COPD Exacerbation Leading to Hospitalization (for 25% Patients)</measure>
    <time_frame>Day 1 to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Patients With at Least on COPD Exacerbation Leading to Hospitalization</measure>
    <time_frame>From Day 1 to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Exacerbation Leading to Hospitalization</measure>
    <time_frame>From Day 1 to 4 years</time_frame>
    <description>Estimated number of exacerbations leading to hospitalizations per patient year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Leading to Hospitalization</measure>
    <time_frame>From Day 1 to 4 years</time_frame>
    <description>Number of days with chronic obstructive pulmonary disease (COPD) exacerbation leading to hospitalization (normalized by treatment exposure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 1</measure>
    <time_frame>Month 1</time_frame>
    <description>Estimated FEV1 before bronchodilator at Month 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 1</measure>
    <time_frame>Month 1</time_frame>
    <description>Estimated forced expiratory volume in one second (FEV1) after bronchodilator at month 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Estimated forced expiratory volume in one second (FEV1) before bronchodilator at month 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 6</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 12</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 12</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 18</measure>
    <time_frame>Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 18</measure>
    <time_frame>Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 24</measure>
    <time_frame>Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 24</measure>
    <time_frame>Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 30</measure>
    <time_frame>Month 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 30</measure>
    <time_frame>Month 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 36</measure>
    <time_frame>Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 36</measure>
    <time_frame>Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 42</measure>
    <time_frame>Month 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 42</measure>
    <time_frame>Month 42</time_frame>
    <description>Estimated FEV1 after bronchodilator at Month 42</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 48</measure>
    <time_frame>Month 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 48</measure>
    <time_frame>Month 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 1</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 1</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 6</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 6</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 12</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 12</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 18</measure>
    <time_frame>Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 18</measure>
    <time_frame>Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 24</measure>
    <time_frame>Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 24</measure>
    <time_frame>Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 30</measure>
    <time_frame>Month 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 30</measure>
    <time_frame>Month 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 36</measure>
    <time_frame>Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 36</measure>
    <time_frame>Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 42</measure>
    <time_frame>Month 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 42</measure>
    <time_frame>Month 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 48</measure>
    <time_frame>Month 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 48</measure>
    <time_frame>Month 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 1</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 1</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 6</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 6</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 12</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 12</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 18</measure>
    <time_frame>Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 18</measure>
    <time_frame>Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 24</measure>
    <time_frame>Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 24</measure>
    <time_frame>Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 30</measure>
    <time_frame>Month 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 30</measure>
    <time_frame>Month 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 36</measure>
    <time_frame>Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 36</measure>
    <time_frame>Month 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 42</measure>
    <time_frame>Month 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 42</measure>
    <time_frame>Month 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 48</measure>
    <time_frame>Month 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 48</measure>
    <time_frame>Month 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 18</measure>
    <time_frame>Month 18</time_frame>
    <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 24</measure>
    <time_frame>Month 24</time_frame>
    <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 30</measure>
    <time_frame>Month 30</time_frame>
    <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 36</measure>
    <time_frame>Month 36</time_frame>
    <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 42</measure>
    <time_frame>Month 42</time_frame>
    <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 48</measure>
    <time_frame>Month 48</time_frame>
    <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Participants With All Cause Death and Time to Event Analysis (On-treatment)</measure>
    <time_frame>Day 1 to completion of double blinded treatment plus 30 days between Day 1 and 4 years plus 30 days</time_frame>
    <description>On-treatment defined as day 1 to completion of double blinded treatment plus 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Participants With All Cause Death (Including Vital Status Follow-up, Cutoff at 1470 Days)</measure>
    <time_frame>Day 1 to day 1470</time_frame>
    <description>All cause mortality vital status information was followed-up after discontinuation; vital status information up to 1470 days after the start of treatment was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Participants With Lower Respiratory Death (On-treatment; Adjudicated Primary Cause)</measure>
    <time_frame>Day 1 to completion of double blinded treatment plus 30 days between Day 1 and 4 years plus 30 days</time_frame>
    <description>The primary cause of death was adjudicated by an external committee prior to unblinding; on-treatment defined as day 1 to completion of double blinded treatment plus 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Participants With a Lower Respiratory Death (Adjudicated; Including Vital Status Follow-up, Cutoff at 1470 Days)</measure>
    <time_frame>Day 1 to day 1470</time_frame>
    <description>The primary cause of death was adjudicated by an external committee prior to unblinding; vital status was information followed-up after discontinuation; vital status information up to 1470 days after the start of treatment was used</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence Rate of Serious Adverse Event (System Organ Class = Cardiac Disorders)</measure>
    <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
    <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence Rate of Serious Adverse Event (Preferred Term = Angina)</measure>
    <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
    <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence Rate of Serious Adverse Event (Preferred Term = Atrial Fibrillation)</measure>
    <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
    <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence Rate of Serious Adverse Event (Preferred Term = Cardiac Failure)</measure>
    <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
    <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence Rate of Serious Adverse Event (Preferred Term = Cardiac Failure Congestive)</measure>
    <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
    <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence Rate of Serious Adverse Event (Preferred Term = Coronary Artery Disease)</measure>
    <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
    <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence Rate of Serious Adverse Event (Preferred Term = Myocardial Infarction)</measure>
    <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
    <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence Rate of Serious Adverse Event (System Organ Class = Lower Respiratory System Disorders)</measure>
    <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
    <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence Rate of Serious Adverse Event (Preferred Term = Bronchitis)</measure>
    <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
    <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence Rate of Serious Adverse Event (Preferred Term = Chronic Obstructive Pulmonary Disease (COPD) Exacerbation)</measure>
    <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
    <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence Rate of Serious Adverse Event (Preferred Term = Dyspnoea)</measure>
    <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
    <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence Rate of Serious Adverse Event (Preferred Term = Pneumonia)</measure>
    <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
    <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence Rate of Serious Adverse Event (Preferred Term = Respiratory Failure)</measure>
    <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
    <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
  </other_outcome>
  <enrollment type="Actual">5993</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Male or female patients 40 years of age or older.

          -  Smoking history of at least 10 pack years.

          -  Diagnosis of COPD with post bronchodilator FEV1 less than or equal to 70% of predicted
             normal and FEV1&lt;70% of FVC and on stable respiratory medication.

        Exclusion Criteria:

          -  Significant diseases other than COPD which in the opinion of the investigator may put
             the patient at risk or influence the patients ability to participate.

          -  Myocardial infarction in past 6 months.

          -  Unstable or life threatening arrhythmia in past year.

          -  Hospitalization for NYHA heart failure class III or IV in past year.

          -  Active tuberculosis.

          -  Asthma.

          -  Pulmonary resection.

          -  Malignancy treated with radiation or chemotherapy in past 5 years.

          -  Respiratory infection in 4 weeks prior to screening.

          -  Known hypersensitivity to anticholinergic drugs or components.

          -  Known moderate to severe renal impairment.

          -  Known narrow angle glaucoma.

          -  Significant symptomatic BPH or bladder neck obstruction.

          -  Need for oxygen therapy &gt;12 hr/day.

          -  Use of oral corticosteroids at unstable doses or &gt;10 mg/day.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>205.235.3779 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3785 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3795 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3759 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3770 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3778 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Escondito</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3810 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3758 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3812 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3773 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3800 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3786 Pulmonary and Critical Care Medicine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3811 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3741 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3717 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3781 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3784 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3760 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sepulveda</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3711 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3764 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3783 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3727 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3808 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3793 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3815 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>WEst Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3706 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3762 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3707 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3703 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3775 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3743 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3756 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3739 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3719 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3790 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3716 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3794 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3724 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3713 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3768 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3749 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3757 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olathe</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3729 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3737 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3788 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3750 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bidderford</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3806 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3721 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3726 354 Birnie Ave</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3813 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3732 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3809 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3751 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3754 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3789 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3734 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3814 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3747 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3763 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3797 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3799 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3796 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3807 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bayshore</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3816 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3765 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Larchmont</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3748 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3818 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3722 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3730 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3731 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3736 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3745 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elizabath City</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3712 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3723 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3701 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3791 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3820 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3725 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3817 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3715 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3742 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3787 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3704 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3752 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3744 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3782 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3771 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3738 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3792 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3761 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3718 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3780 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.101</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.103 Hospital Alemán</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.104 Hospital de Clinicas José de San Martín</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.105 Hospital General de Agudos José María Ramos Mejía</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.107 Policlínica Bancaria</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.108 Hospital General de Agudos Dr. Enrique Tornú</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.109 Hospital Muñiz</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.110 Hospital Privado - Centro Médico de Córdoba S.A.</name>
      <address>
        <city>Parque Velez Sarlfield</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.102 Instituto Cardiovascular de Rosario</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.106 Hospital Cetrángolo</name>
      <address>
        <city>Vicente López</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bankstown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0209 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Redcliffe</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Port Lincoln</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leoben</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0439 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Anderlecht</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0429 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baudour</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0421 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0424 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0432 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0434 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0422 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dendermonde</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0414 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0418 U.Z. Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0417 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Herentals</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ieper</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0409 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0440 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Luxembourg</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Menen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Middelheim</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0438 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mons</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0437 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0420 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neerpelt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0435 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nobressart (ATTERT)</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0423 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oostende</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0433 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tournai</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0412 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0413 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0428 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.510 Servico de Pneumologia</name>
      <address>
        <city>Florianópolis - SC</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.508</name>
      <address>
        <city>Juiz de Fora - MG</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.501</name>
      <address>
        <city>Porto Alegre - RS</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.503</name>
      <address>
        <city>Porto Alegre - RS</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.506</name>
      <address>
        <city>Porto Alegre - RS</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.507 Depto.de Medicina Interna-Servico de pneumologia</name>
      <address>
        <city>Porto Alegre - RS</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.502</name>
      <address>
        <city>Rio de Janeiro - RJ</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.505 Dep.Medicina Especializada (DEMESP)</name>
      <address>
        <city>Rio de Janeiro - RJ</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.511 Departamento de Pneumologia</name>
      <address>
        <city>Salvador - BA</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.504 ANEXO 2-Laboratório de Funcao Pulmonar</name>
      <address>
        <city>Santo André - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.512</name>
      <address>
        <city>São Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.513</name>
      <address>
        <city>São Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.514 Unidade de Coracao e Pulmao do Dto. de Medicina</name>
      <address>
        <city>São Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.515 Lar Escola São Francisco / Setor de Pneumologia</name>
      <address>
        <city>São Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0712 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Benesov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0711 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beroun</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0718 Clinic of Functional Diagnostics and Rehabilitation</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0725 University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0720 Office of Pulmonology and Respiratory Diseases</name>
      <address>
        <city>Cesky Tesin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0717 Pulmonary Clinic</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0705 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jablonec nad Nisou</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0726 Private Office of Pulmonary Diseases</name>
      <address>
        <city>Jaromer</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0722 Hospital Kromeriz</name>
      <address>
        <city>Kromeriz</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0724 District Hospital Kyjov</name>
      <address>
        <city>Kyjov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0704 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lovosice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0702 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marianske Lazne</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0701 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plzen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0703 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plzen</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0710 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prague 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0706 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 4</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0709 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 4</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0708 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 5 - Nove Butovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0715 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0707 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Praha 8</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0723 Office of Pulmonary and Respiratory Diseases</name>
      <address>
        <city>Prerov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0721 Office of Pulmonary Diseases</name>
      <address>
        <city>Pribor</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0713 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Strakonice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0714 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tabor</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0719 Office of Pulmonology and Respiratory Diseases</name>
      <address>
        <city>Usti nad Orlici</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0716 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Znojmo</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0826 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aalborg SV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0828 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Copenhagen K</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Copenhagen NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0831 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0821 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frederikshavn</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0832 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frederikssund</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0807 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fåborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0805 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0835 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0816 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsingor</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0811 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0834 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hobro</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0806 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Holbæk</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0814 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Holstebro</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0833 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kalundborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0830 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kolding</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0819 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nykobing F.</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0810 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Næstved</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0809 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odense C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0815 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Randers</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0824 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Silkeborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0813 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Skive</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0822 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Skive</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0820 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Slagelse</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0808 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Svendborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0827 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Værløse</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jyväskylä</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kotka</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pori</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1004 Clinique Toulouse Lautrec</name>
      <address>
        <city>Albi cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1007 Cabinet Médical</name>
      <address>
        <city>Albi</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1015 Centre Hospitalier</name>
      <address>
        <city>Barbezieux St Hilaire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1012 Cabinet Médical</name>
      <address>
        <city>Bourges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1024 Cabinet Médical</name>
      <address>
        <city>Chamalières</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1006 Centre Hospitalier de Chauny</name>
      <address>
        <city>Chauny cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1005 Polyclinique</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1013 Cabinet Médical</name>
      <address>
        <city>La Teste</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1020 Cabinet Médical</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1023 Cabinet Médical</name>
      <address>
        <city>Montauban</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1025 Centre Médical Erdre Saint Augustin</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1002 Cabinet médical</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1001 Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1016 Cabinet Médical</name>
      <address>
        <city>Provins</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1019 Cabinet Médical</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1009 Centre Hospitalier de Bigorre</name>
      <address>
        <city>Tarbes cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1021 Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1114 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brake</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Braunschweig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruchsal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1115 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaufbeuren</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lörrach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Weyhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wiesloch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1202 8th Pulmonology Clinic &quot;Sotiria&quot; Athens Chest Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1211 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kavala</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1209 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Patra</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1210 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Patra</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1308 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1309 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1310 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1311 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1318 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1314 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1306 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erd</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1315 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Farkasgyepü</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1320 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1307 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiskunhalas</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1317 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mosonmagyarovar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1313 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Solymar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1305 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sopron</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1319 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tatabanya</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1316 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Törökbalint</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1312 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Veszprem</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1505 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin 15</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin 4</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin 9</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1631 A. O. SS. Antonio e Biagio e Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1613 A. O. S. Giuseppe Moscati</name>
      <address>
        <city>Avellino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1618 Ospedale Bellaria</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1649 Ospedale di Circolo di Busto Arsizio</name>
      <address>
        <city>Busto Arsizio (VA)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1635 P. O. Roberto Binaghi</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1623 A. O. di Carrara</name>
      <address>
        <city>Carrara (Massa)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1645 Ospedale Civile &quot;Zappatoni&quot;</name>
      <address>
        <city>CASSANO D'ADDA (Milano)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1617 Ospedale S. Camillo De Lellis</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1612 A. O. S. Antonio Abate</name>
      <address>
        <city>Erice (Trapani)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1622 A. O. S. Anna</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1646 A. O. di Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1647 A. O. Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1615 Ospedale S. Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1603 P. O. di Gubbio</name>
      <address>
        <city>Gubbio (Perugia)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1619 A. O. Fratelli Crobu</name>
      <address>
        <city>Iglesias (Cagliari)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1648 Ospedale &quot;S. Maria di Collemaggio&quot;</name>
      <address>
        <city>L'Aquila</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1624 Ospedale di Macerata</name>
      <address>
        <city>Macerata</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1634 P. O. Luigi Sacco</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1639 Ospedale Maggiore</name>
      <address>
        <city>Modica (Ragusa)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1629 A. O. S. Luigi Gonzaga</name>
      <address>
        <city>Orbassano (Torino)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1604 P. O. R. Silvestrini</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1601 Presidio Ospedaliero di Cisanello</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1643 A. O. Santa Maria degli Angeli</name>
      <address>
        <city>Pordenone</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1614 Ospedale Misericordia e Dolce</name>
      <address>
        <city>Prato</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1607 Università degli Studi di Sassari</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1608 ASL 1 di Sassari</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1606 ASL 4 di Terni</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1632 ASL 4 - Distretto 2</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1633 A. O. Umberto I</name>
      <address>
        <city>Torrette di Ancona (Ancona)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1640 P. O. Cà Foncello</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1602 Ospedale di Voghera</name>
      <address>
        <city>Voghera (Pavia)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1706 Juntendo University Hospital</name>
      <address>
        <city>Bunkyo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1705 Kameda Medical Center</name>
      <address>
        <city>Kamogawa, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1713 Komaki City Hospital</name>
      <address>
        <city>Komaki, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1712 Kurume University Hospital</name>
      <address>
        <city>Kurume, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1708 Shinshu University</name>
      <address>
        <city>Matsumoto, Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1702 Iwate Medical University Hospital</name>
      <address>
        <city>Morioka, Iwate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1710 Osaka City University Hospital</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1711 Kinki University Hospital</name>
      <address>
        <city>Osakasayama, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1701 Hokkaido University</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1703 Tohoku University Hospital</name>
      <address>
        <city>Sendai, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1709 Tosei General Hospital</name>
      <address>
        <city>Seto, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1704 Hiraka General Hospital</name>
      <address>
        <city>Yokote, Akita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2005</name>
      <address>
        <city>Ciudad de Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2006 Tlalpan 4000, Pabellón 5, EPOC</name>
      <address>
        <city>Ciudad de Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2004 Edif. Dr. Rodrigo F. Barragan, P.B.</name>
      <address>
        <city>Col. Mitras Centro, Monterrey, N.L.</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2002</name>
      <address>
        <city>Guadalajara, Jal.</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2009</name>
      <address>
        <city>Puebla</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2010 Depto. De Ivestigación</name>
      <address>
        <city>Toluca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2003</name>
      <address>
        <city>Zapopan, jalisco</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2110 Poli Longziekten</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2105 Lokatie De Lichtenberg</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2107 Poli Longziekten</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2106 Lokatie Dordwijk</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2104 Poli longziekten</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2102 Martini Ziekenhuis Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2112 Poli Longziekten</name>
      <address>
        <city>Harderwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2115 Poli Longziekten</name>
      <address>
        <city>Heerenveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2101 Atrium medisch centrum</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2114 Poli Longziekten</name>
      <address>
        <city>Hengelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2108 Poli Longziekten</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2109 Poli Longziekten</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2111 Antonius Ziekenhuis</name>
      <address>
        <city>Sneek</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0211 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.0212 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Christchurch, New Zealand</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arendal</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fredrikstad</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sandvika</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Straume</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2301 Philippine General Hospital</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2305 University of Santo Tomas Hospital</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2302 Philippine Heart Center</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2303 Veterans Memorial Medical Center</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2304 Lung Center of the Philippines</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2410 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2407 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2408 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2409 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2406 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zabrze</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2504 Centro Hospitalar de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2503 Hospital Pulido Valente</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2505 Hospital de Santa Marta</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2501 Hospital de São João</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2502 Centro Hospitalar de Vila Nova de Gaia</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2604 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.1906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2701 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2702 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2703 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2704 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poprad</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2705 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Topolcany</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Golnik</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Golnik</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2805 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kamnik</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Topolsica</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2908</name>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2910</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2912</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2904</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2911</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2902</name>
      <address>
        <city>George</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2905</name>
      <address>
        <city>Paarl</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2906</name>
      <address>
        <city>Somerset West</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2903</name>
      <address>
        <city>Vanderbijlpark</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.2909</name>
      <address>
        <city>Welkom</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3014 Complejo Hospitalario Juan Canalejo</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3026 Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3011 Complejo Hospitalario Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3006 Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3022 Hospital de Cruces</name>
      <address>
        <city>Barakaldo (Bilbao)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3003 Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3008 Hospital Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3023 Hospital Dr. Josep Trueta</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3004 Hospital General Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3005 Hospital General San Jorge de Huesca</name>
      <address>
        <city>Huesca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3021 Hospital de Jerez de la Frontera</name>
      <address>
        <city>Jerez de la Frontera</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3010 Hospital Severo Ochoa</name>
      <address>
        <city>Leganés, Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3009 Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3013 Clínica Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3017 Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3020 Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3028 Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3031 Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3036 Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3033 Hospital General Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3027 Complejo Asistencial Son Dureta</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3024 Hospital de Montecelo</name>
      <address>
        <city>Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3016 Hospital Universitari de Sant Joan</name>
      <address>
        <city>Reus (Tarragona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3015 Corporació Sanitaria Parc Taulí de Sabadell</name>
      <address>
        <city>Sabadell (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3037 Hsopital Universitario Ntra. Sra. de la Candelaria</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3039 Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3019 Hospital Vírgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3035 Hospital Universitario Vírgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3001 Hospital Mutua Terrassa</name>
      <address>
        <city>Terrassa (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3002 Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3025 Hospital Universitario Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3032 Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3034 Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3018 Complejo Hospitalario Xeral - Cíes</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3030 Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3038 Hospital Clínico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3203 Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Faltigberg</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montana</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3208 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winterthur</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3302 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3402 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3403 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3404 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3401 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3405 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3510 Cukurova Tip Fakultesi Balcali Hastanesi</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3506 Hacettepe Tip Fakultesi</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3507 Ankara SSK Diskapi Egitim Hastanesi</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3508 Atatürk Gögüs Hastaliklari ve Gögüs Cerrahi</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3509 Atatürk Üniversitesi Tip Fakultesi Aziziye</name>
      <address>
        <city>Erzurum</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3511 Osmangazi Universitesi Tip Fakültesi</name>
      <address>
        <city>Eskisehir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3501 Istanbul Universitesi Cerrahpasa Tip Fakultesi</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3502 Yedikule Gögüs Hastaliklari Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3503 Tophanelioglu Cad. No: 13/15</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3504 Cevizli E5 Karayolu</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3505 Istanbul Universitesi Tip Fakültesi</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3512 DokuzEylül Universitesi Tip Fakultesi Gögüs Hastaliklari ABD</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3615 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3611 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chertsey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3613 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3608 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cottingham, Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3610 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3607 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3604 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Middleton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3612 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3616 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paisley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3614 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Penarth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3609 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.235.3601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Solihull, Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <results_first_submitted>February 21, 2009</results_first_submitted>
  <results_first_submitted_qc>July 3, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 17, 2009</results_first_posted>
  <last_update_submitted>May 15, 2014</last_update_submitted>
  <last_update_submitted_qc>May 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>09 Jan 2003 – 22 Feb 2008; 490 centers in 37 countries</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>once daily</description>
        </group>
        <group group_id="P2">
          <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
          <description>once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3006"/>
                <participants group_id="P2" count="2986"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1648"/>
                <participants group_id="P2" count="1887"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1358"/>
                <participants group_id="P2" count="1099"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="746"/>
                <participants group_id="P2" count="627"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="403"/>
                <participants group_id="P2" count="300"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Once daily</description>
        </group>
        <group group_id="B2">
          <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
          <description>Once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3006"/>
            <count group_id="B2" value="2986"/>
            <count group_id="B3" value="5992"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.52" spread="8.48"/>
                    <measurement group_id="B2" value="64.50" spread="8.41"/>
                    <measurement group_id="B3" value="64.51" spread="8.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="784"/>
                    <measurement group_id="B2" value="735"/>
                    <measurement group_id="B3" value="1519.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2222"/>
                    <measurement group_id="B2" value="2251"/>
                    <measurement group_id="B3" value="4473.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years</title>
        <description>Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.</description>
        <time_frame>From day 30 to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years</title>
          <description>Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.</description>
          <units>ml/year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2413"/>
                <count group_id="O2" value="2557"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30" spread="1"/>
                    <measurement group_id="O2" value="-30" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear random effects model</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9524</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Random-effects model</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
            <estimate_desc>Arbitrary covariance matrix; fixed treatment effect; individual patients are random; rate of decline estimated as the slope of the random effects model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years</title>
        <description>Rate of decline of forced expiratory volume in one second (FEV1) measured after bronchodilation. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.</description>
        <time_frame>From day 30 to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years</title>
          <description>Rate of decline of forced expiratory volume in one second (FEV1) measured after bronchodilation. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1.</description>
          <units>ml/year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2410"/>
                <count group_id="O2" value="2554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42" spread="1"/>
                    <measurement group_id="O2" value="-40" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear random effects model</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2074</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Random-effects model</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>6</ci_upper_limit>
            <estimate_desc>Arbitrary covariance matrix; fixed treatment effect; individual patients are random; rate of decline estimated as the slope of the random effects model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment</title>
        <description>Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1</description>
        <time_frame>Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment</title>
          <description>Rate of decline of forced expiratory volume in one second (FEV1) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1</description>
          <units>ml/year</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1618"/>
                <count group_id="O2" value="1803"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17" spread="2"/>
                    <measurement group_id="O2" value="-15" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2488</p_value>
            <method>Wilcoxon Rank-sum test</method>
            <method_desc>Rate calculated as (measure on 30days after completion of treatment - measure on day 1 )/ years in between</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment</title>
        <description>Rate of decline of forced expiratory volume in one second (FEV1) measured after the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1</description>
        <time_frame>Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment</title>
          <description>Rate of decline of forced expiratory volume in one second (FEV1) measured after the use of bronchodilators. A negative rate of decline indicates decreasing FEV1 over time, while a positive value indicates increasing FEV1</description>
          <units>ml/year</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1613"/>
                <count group_id="O2" value="1805"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32" spread="2"/>
                    <measurement group_id="O2" value="-27" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0145</p_value>
            <method>Wilcoxon Rank-sum test</method>
            <method_desc>Rate calculated as (measure on 30days after completion of treatment - measure on day 1 )/ years in between</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years</title>
        <description>Rate of decline of forced vital capacity (FVC) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC</description>
        <time_frame>From day 30 to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years</title>
          <description>Rate of decline of forced vital capacity (FVC) measured before the use of bronchodilators. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC</description>
          <units>ml/year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2413"/>
                <count group_id="O2" value="2557"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39" spread="3"/>
                    <measurement group_id="O2" value="-43" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear random effects model</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2990</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-12</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
            <estimate_desc>Arbitrary covariance matrix; fixed treatment effect; individual patients are random; rate of decline estimated as the slope of the random effects model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years</title>
        <description>Rate of decline of forced vital capacity (FVC) measured after bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC</description>
        <time_frame>From day 30 to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 30 to 4 Years</title>
          <description>Rate of decline of forced vital capacity (FVC) measured after bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC</description>
          <units>ml/year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2410"/>
                <count group_id="O2" value="2554"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61" spread="3"/>
                    <measurement group_id="O2" value="-61" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear random effects model</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8375</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9</ci_lower_limit>
            <ci_upper_limit>7</ci_upper_limit>
            <estimate_desc>Arbitrary covariance matrix; fixed treatment effect; individual patients are random; rate of decline estimated as the slope of the random effects model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years</title>
        <description>Rate of decline of slow vital capacity (SVC) measured before the use of bronchodilators. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC</description>
        <time_frame>From day 30 to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years</title>
          <description>Rate of decline of slow vital capacity (SVC) measured before the use of bronchodilators. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC</description>
          <units>ml/year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2531"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41" spread="3"/>
                    <measurement group_id="O2" value="-47" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear random effects model</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1143</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-14</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
            <estimate_desc>Arbitrary covariance matrix; fixed treatment effect; individual patients are random; rate of decline estimated as the slope of the random effects model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years</title>
        <description>Rate of decline of slow vital capacity (SVC) measured after bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC</description>
        <time_frame>From day 30 to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 30 to 4 Years</title>
          <description>Rate of decline of slow vital capacity (SVC) measured after bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC</description>
          <units>ml/year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2383"/>
                <count group_id="O2" value="2527"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65" spread="3"/>
                    <measurement group_id="O2" value="-66" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear random effects model</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7870</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9</ci_lower_limit>
            <ci_upper_limit>7</ci_upper_limit>
            <estimate_desc>Arbitrary covariance matrix; fixed treatment effect; individual patients are random; rate of decline estimated as the slope of the random effects model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Decline of St George's Respiratory Questionnaire (SGRQ) Total Score</title>
        <description>SGRQ total score shows the impact of COPD on patient's health status, and expressed as a percentage of impairment with scale from 0 (best health status) to 100 (worst possible status). A negative rate of decline shows decreasing SGRQ total score (or improved health) over time, while a positive value shows increasing score (or worsen health).</description>
        <time_frame>From month 6 to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Decline of St George's Respiratory Questionnaire (SGRQ) Total Score</title>
          <description>SGRQ total score shows the impact of COPD on patient's health status, and expressed as a percentage of impairment with scale from 0 (best health status) to 100 (worst possible status). A negative rate of decline shows decreasing SGRQ total score (or improved health) over time, while a positive value shows increasing score (or worsen health).</description>
          <units>Score on scale per year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2362"/>
                <count group_id="O2" value="2505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="0.09"/>
                    <measurement group_id="O2" value="1.25" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear random effects model</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7840</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
            <estimate_desc>Arbitrary covariance matrix; fixed treatment effect; individual patients are random; rate of decline estimated as the slope of the random effects model</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment</title>
        <description>Rate of decline of forced vital capacity (FVC) before bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC</description>
        <time_frame>Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment</title>
          <description>Rate of decline of forced vital capacity (FVC) before bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC</description>
          <units>ml/year</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1618"/>
                <count group_id="O2" value="1803"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12" spread="4"/>
                    <measurement group_id="O2" value="-10" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2705</p_value>
            <method>Wilcoxon Rank-sum test</method>
            <method_desc>Rate calculated as (measure on 30days after completion of treatment - measure on day 1 )/ years in between</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment</title>
        <description>Rate of decline of forced vital capacity (FVC) after bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC</description>
        <time_frame>Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator Forced Vital Capacity (FVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment</title>
          <description>Rate of decline of forced vital capacity (FVC) after bronchodilation. A negative rate of decline indicates decreasing FVC over time, while a positive value indicates increasing FVC</description>
          <units>ml/year</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1613"/>
                <count group_id="O2" value="1805"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40" spread="4"/>
                    <measurement group_id="O2" value="-40" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.306</p_value>
            <method>Wilcoxon Rank-sum test</method>
            <method_desc>Rate calculated as (measure on 30days after completion of treatment - measure on day 1 )/ years in between</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment</title>
        <description>Rate of decline slow vital capacity (SVC) before bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC</description>
        <time_frame>Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment</title>
          <description>Rate of decline slow vital capacity (SVC) before bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC</description>
          <units>ml/year</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1562"/>
                <count group_id="O2" value="1706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17" spread="4"/>
                    <measurement group_id="O2" value="-17" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8103</p_value>
            <method>Wilcoxon Rank-sum test</method>
            <method_desc>Rate calculated as (measure on 30days after completion of treatment - measure on day 1 )/ years in between</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment</title>
        <description>Rate of decline of slow vital capacity (SVC) after bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC</description>
        <time_frame>Day 1 to 30 days after completion of double blinded treatment between Day 1 and 4 years plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator Slow Vital Capacity (SVC) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment</title>
          <description>Rate of decline of slow vital capacity (SVC) after bronchodilation. A negative rate of decline indicates decreasing SVC over time, while a positive value indicates increasing SVC</description>
          <units>ml/year</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1540"/>
                <count group_id="O2" value="1711"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46" spread="4"/>
                    <measurement group_id="O2" value="-42" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9814</p_value>
            <method>Wilcoxon Rank-sum test</method>
            <method_desc>Rate calculated as (measure on 30days after completion of treatment - measure on day 1 )/ years in between</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Exacerbation</title>
        <description>Chronic obstructive pulmonary disease (COPD) exacerbation</description>
        <time_frame>From Day 1 to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Exacerbation</title>
          <description>Chronic obstructive pulmonary disease (COPD) exacerbation</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.51" lower_limit="11.53" upper_limit="13.79"/>
                    <measurement group_id="O2" value="16.65" lower_limit="14.88" upper_limit="17.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cox regression</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <method_desc>Cox regression with treatment</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
            <estimate_desc>Median estimated by Kaplan-Meier estimates; hazard ratio shown as tio vs. placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient Year</title>
        <time_frame>Day 1 to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient Year</title>
          <units>number per patient year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.02"/>
                    <measurement group_id="O2" value="0.73" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poisson regression adjusted for overdispersion and treatment exposure</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
            <estimate_desc>Ratio calculated as estimated number of events in tio/number of events in placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Patients With at Least One Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
        <time_frame>Day 1 to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Patients With at Least One Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2049"/>
                    <measurement group_id="O2" value="2001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3481</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Exacerbation Days Per Patient Year</title>
        <description>Number of exacerbation days normalized by treatment exposure</description>
        <time_frame>Day 1 to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Exacerbation Days Per Patient Year</title>
          <description>Number of exacerbation days normalized by treatment exposure</description>
          <units>days/patient year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.64" spread="0.35"/>
                    <measurement group_id="O2" value="12.11" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poisson regression adjusted for overdispersion and treatment exposure</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
            <estimate_desc>Poisson regression adjusting for overdispersion with Pearson’s method adjusting for treatment exposure. The logarithm of treatment exposure is used as offset when building the Poisson model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First COPD Exacerbation Leading to Hospitalization (for 25% Patients)</title>
        <time_frame>Day 1 to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First COPD Exacerbation Leading to Hospitalization (for 25% Patients)</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.64" lower_limit="26.08" upper_limit="31.82"/>
                    <measurement group_id="O2" value="35.89" lower_limit="23.38" upper_limit="39.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1766</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Patients With at Least on COPD Exacerbation Leading to Hospitalization</title>
        <time_frame>From Day 1 to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Patients With at Least on COPD Exacerbation Leading to Hospitalization</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="811"/>
                    <measurement group_id="O2" value="759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cox regression</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0024</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
            <estimate_desc>Hazard ratio shown as tiotropium bromide vs. placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Exacerbation Leading to Hospitalization</title>
        <description>Estimated number of exacerbations leading to hospitalizations per patient year</description>
        <time_frame>From Day 1 to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Exacerbation Leading to Hospitalization</title>
          <description>Estimated number of exacerbations leading to hospitalizations per patient year</description>
          <units>Number per patient year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16"/>
                    <measurement group_id="O2" value="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3413</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>Ratio of estimated number of events between tiotropium bromide and placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Leading to Hospitalization</title>
        <description>Number of days with chronic obstructive pulmonary disease (COPD) exacerbation leading to hospitalization (normalized by treatment exposure)</description>
        <time_frame>From Day 1 to 4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Days of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Leading to Hospitalization</title>
          <description>Number of days with chronic obstructive pulmonary disease (COPD) exacerbation leading to hospitalization (normalized by treatment exposure)</description>
          <units>days/patient year</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" spread="0.17"/>
                    <measurement group_id="O2" value="3.17" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poisson regression adjusting for overdispersion with Pearson’s method adjusting for treatment exposure. The logarithm of treatment exposure is used as offset when building the Poisson model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8624</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Rate ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>Ratio of estimated number of days of chronic obstructive pulmonary disease (COPD) exacerbation leading to hospitalization between tio and placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 1</title>
        <description>Estimated FEV1 before bronchodilator at Month 1</description>
        <time_frame>Month 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 1</title>
          <description>Estimated FEV1 before bronchodilator at Month 1</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.134" spread="0.004"/>
                    <measurement group_id="O2" value="1.221" spread="0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.087</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.077</ci_lower_limit>
            <ci_upper_limit>0.098</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 1</title>
        <description>Estimated forced expiratory volume in one second (FEV1) after bronchodilator at month 1</description>
        <time_frame>Month 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 1</title>
          <description>Estimated forced expiratory volume in one second (FEV1) after bronchodilator at month 1</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.372" spread="0.004"/>
                    <measurement group_id="O2" value="1.418" spread="0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.047</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.037</ci_lower_limit>
            <ci_upper_limit>0.057</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 6</title>
        <description>Estimated forced expiratory volume in one second (FEV1) before bronchodilator at month 6</description>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 6</title>
          <description>Estimated forced expiratory volume in one second (FEV1) before bronchodilator at month 6</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.126" spread="0.004"/>
                    <measurement group_id="O2" value="1.225" spread="0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.099</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.087</ci_lower_limit>
            <ci_upper_limit>0.110</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 6</title>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 6</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.365" spread="0.004"/>
                    <measurement group_id="O2" value="1.423" spread="0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.058</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.047</ci_lower_limit>
            <ci_upper_limit>0.069</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 12</title>
        <time_frame>Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 12</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.111" spread="0.004"/>
                    <measurement group_id="O2" value="1.213" spread="0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.103</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.091</ci_lower_limit>
            <ci_upper_limit>0.115</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 12</title>
        <time_frame>Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 12</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.345" spread="0.004"/>
                    <measurement group_id="O2" value="1.398" spread="0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.054</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.042</ci_lower_limit>
            <ci_upper_limit>0.065</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 18</title>
        <time_frame>Month 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 18</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.101" spread="0.005"/>
                    <measurement group_id="O2" value="1.192" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.091</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.078</ci_lower_limit>
            <ci_upper_limit>0.104</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 18</title>
        <time_frame>Month 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 18</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.326" spread="0.005"/>
                    <measurement group_id="O2" value="1.379" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.053</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.040</ci_lower_limit>
            <ci_upper_limit>0.066</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 24</title>
        <time_frame>Month 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 24</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.079" spread="0.005"/>
                    <measurement group_id="O2" value="1.173" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.094</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.081</ci_lower_limit>
            <ci_upper_limit>0.107</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 24</title>
        <time_frame>Month 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 24</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.294" spread="0.005"/>
                    <measurement group_id="O2" value="1.356" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.062</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.049</ci_lower_limit>
            <ci_upper_limit>0.075</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 30</title>
        <time_frame>Month 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 30</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.061" spread="0.005"/>
                    <measurement group_id="O2" value="1.156" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.095</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.081</ci_lower_limit>
            <ci_upper_limit>0.109</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 30</title>
        <time_frame>Month 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 30</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.274" spread="0.005"/>
                    <measurement group_id="O2" value="1.335" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.061</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.047</ci_lower_limit>
            <ci_upper_limit>0.075</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 36</title>
        <time_frame>Month 36</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 36</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.045" spread="0.005"/>
                    <measurement group_id="O2" value="1.144" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.099</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.085</ci_lower_limit>
            <ci_upper_limit>0.114</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 36</title>
        <time_frame>Month 36</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 36</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.250" spread="0.005"/>
                    <measurement group_id="O2" value="1.315" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.065</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.051</ci_lower_limit>
            <ci_upper_limit>0.080</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 42</title>
        <time_frame>Month 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 42</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.034" spread="0.005"/>
                    <measurement group_id="O2" value="1.129" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.095</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.080</ci_lower_limit>
            <ci_upper_limit>0.110</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 42</title>
        <description>Estimated FEV1 after bronchodilator at Month 42</description>
        <time_frame>Month 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 42</title>
          <description>Estimated FEV1 after bronchodilator at Month 42</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.236" spread="0.006"/>
                    <measurement group_id="O2" value="1.297" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.061</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.045</ci_lower_limit>
            <ci_upper_limit>0.076</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 48</title>
        <time_frame>Month 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 48</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.024" spread="0.006"/>
                    <measurement group_id="O2" value="1.112" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.088</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.073</ci_lower_limit>
            <ci_upper_limit>0.103</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 48</title>
        <time_frame>Month 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Month 48</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.219" spread="0.006"/>
                    <measurement group_id="O2" value="1.268" spread="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.049</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.033</ci_lower_limit>
            <ci_upper_limit>0.065</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 1</title>
        <time_frame>Month 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 1</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.667" spread="0.008"/>
                    <measurement group_id="O2" value="2.856" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.190</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.168</ci_lower_limit>
            <ci_upper_limit>0.211</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 1</title>
        <time_frame>Month 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 1</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.149" spread="0.007"/>
                    <measurement group_id="O2" value="3.204" spread="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.055</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.037</ci_lower_limit>
            <ci_upper_limit>0.073</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 6</title>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 6</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.658" spread="0.009"/>
                    <measurement group_id="O2" value="2.862" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.204</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.180</ci_lower_limit>
            <ci_upper_limit>0.228</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 6</title>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 6</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.137" spread="0.008"/>
                    <measurement group_id="O2" value="3.193" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.055</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.034</ci_lower_limit>
            <ci_upper_limit>0.076</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 12</title>
        <time_frame>Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 12</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.640" spread="0.009"/>
                    <measurement group_id="O2" value="2.838" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.198</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.173</ci_lower_limit>
            <ci_upper_limit>0.222</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 12</title>
        <time_frame>Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 12</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.110" spread="0.008"/>
                    <measurement group_id="O2" value="3.158" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.048</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.026</ci_lower_limit>
            <ci_upper_limit>0.070</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 18</title>
        <time_frame>Month 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 18</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.622" spread="0.010"/>
                    <measurement group_id="O2" value="2.816" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.194</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.167</ci_lower_limit>
            <ci_upper_limit>0.221</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 18</title>
        <time_frame>Month 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 18</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.075" spread="0.009"/>
                    <measurement group_id="O2" value="3.126" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.050</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.026</ci_lower_limit>
            <ci_upper_limit>0.074</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 24</title>
        <time_frame>Month 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 24</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.597" spread="0.010"/>
                    <measurement group_id="O2" value="2.785" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.189</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.161</ci_lower_limit>
            <ci_upper_limit>0.216</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 24</title>
        <time_frame>Month 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 24</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.036" spread="0.009"/>
                    <measurement group_id="O2" value="3.095" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.059</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.035</ci_lower_limit>
            <ci_upper_limit>0.084</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 30</title>
        <time_frame>Month 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 30</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.572" spread="0.010"/>
                    <measurement group_id="O2" value="2.757" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.185</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.157</ci_lower_limit>
            <ci_upper_limit>0.213</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 30</title>
        <time_frame>Month 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 30</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.010" spread="0.010"/>
                    <measurement group_id="O2" value="3.057" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.047</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.021</ci_lower_limit>
            <ci_upper_limit>0.074</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 36</title>
        <time_frame>Month 36</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 36</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.553" spread="0.011"/>
                    <measurement group_id="O2" value="2.753" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.200</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.170</ci_lower_limit>
            <ci_upper_limit>0.229</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 36</title>
        <time_frame>Month 36</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 36</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.973" spread="0.010"/>
                    <measurement group_id="O2" value="3.038" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.065</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.038</ci_lower_limit>
            <ci_upper_limit>0.093</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 42</title>
        <time_frame>Month 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 42</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.540" spread="0.011"/>
                    <measurement group_id="O2" value="2.724" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.184</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.154</ci_lower_limit>
            <ci_upper_limit>0.215</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 42</title>
        <time_frame>Month 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 42</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.959" spread="0.011"/>
                    <measurement group_id="O2" value="3.005" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.046</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.017</ci_lower_limit>
            <ci_upper_limit>0.076</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 48</title>
        <time_frame>Month 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Forced Vital Capacity (FVC) at Month 48</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2363"/>
                <count group_id="O2" value="2494"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.532" spread="0.011"/>
                    <measurement group_id="O2" value="2.702" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.170</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.139</ci_lower_limit>
            <ci_upper_limit>0.201</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 48</title>
        <time_frame>Month 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Forced Vital Capacity (FVC) at Month 48</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2374"/>
                <count group_id="O2" value="2516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.929" spread="0.011"/>
                    <measurement group_id="O2" value="2.961" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0365</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.032</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.002</ci_lower_limit>
            <ci_upper_limit>0.061</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 1</title>
        <time_frame>Month 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 1</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2325"/>
                <count group_id="O2" value="2447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.847" spread="0.008"/>
                    <measurement group_id="O2" value="3.017" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.170</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.147</ci_lower_limit>
            <ci_upper_limit>0.192</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 1</title>
        <time_frame>Month 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 1</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2340"/>
                <count group_id="O2" value="2467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.280" spread="0.007"/>
                    <measurement group_id="O2" value="3.318" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.038</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.018</ci_lower_limit>
            <ci_upper_limit>0.058</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 6</title>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 6</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2325"/>
                <count group_id="O2" value="2447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.841" spread="0.009"/>
                    <measurement group_id="O2" value="3.027" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.186</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.161</ci_lower_limit>
            <ci_upper_limit>0.210</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 6</title>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 6</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2340"/>
                <count group_id="O2" value="2467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.268" spread="0.008"/>
                    <measurement group_id="O2" value="3.304" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0018</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.037</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.014</ci_lower_limit>
            <ci_upper_limit>0.060</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 12</title>
        <time_frame>Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 12</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2325"/>
                <count group_id="O2" value="2447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.820" spread="0.009"/>
                    <measurement group_id="O2" value="2.996" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.176</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.151</ci_lower_limit>
            <ci_upper_limit>0.201</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 12</title>
        <time_frame>Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 12</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2340"/>
                <count group_id="O2" value="2467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.228" spread="0.008"/>
                    <measurement group_id="O2" value="3.260" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0069</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.032</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.055</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 18</title>
        <time_frame>Month 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 18</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2325"/>
                <count group_id="O2" value="2447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.811" spread="0.010"/>
                    <measurement group_id="O2" value="2.965" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.154</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.127</ci_lower_limit>
            <ci_upper_limit>0.182</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 18</title>
        <time_frame>Month 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 18</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2340"/>
                <count group_id="O2" value="2467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.195" spread="0.009"/>
                    <measurement group_id="O2" value="3.234" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.040</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.015</ci_lower_limit>
            <ci_upper_limit>0.065</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 24</title>
        <time_frame>Month 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 24</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2325"/>
                <count group_id="O2" value="2447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.775" spread="0.010"/>
                    <measurement group_id="O2" value="2.942" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.167</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.139</ci_lower_limit>
            <ci_upper_limit>0.194</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 24</title>
        <time_frame>Month 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 24</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2340"/>
                <count group_id="O2" value="2467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.157" spread="0.009"/>
                    <measurement group_id="O2" value="3.189" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0165</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.032</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.006</ci_lower_limit>
            <ci_upper_limit>0.057</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 30</title>
        <time_frame>Month 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 30</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2325"/>
                <count group_id="O2" value="2447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.738" spread="0.011"/>
                    <measurement group_id="O2" value="2.908" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.170</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.141</ci_lower_limit>
            <ci_upper_limit>0.199</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 30</title>
        <time_frame>Month 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 30</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2340"/>
                <count group_id="O2" value="2467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.126" spread="0.010"/>
                    <measurement group_id="O2" value="3.157" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0248</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.031</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.004</ci_lower_limit>
            <ci_upper_limit>0.059</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 36</title>
        <time_frame>Month 36</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 36</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2325"/>
                <count group_id="O2" value="2447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.731" spread="0.011"/>
                    <measurement group_id="O2" value="2.897" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.166</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.136</ci_lower_limit>
            <ci_upper_limit>0.196</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 36</title>
        <time_frame>Month 36</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 36</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2340"/>
                <count group_id="O2" value="2467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.086" spread="0.010"/>
                    <measurement group_id="O2" value="3.136" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.050</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.022</ci_lower_limit>
            <ci_upper_limit>0.078</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 42</title>
        <time_frame>Month 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 42</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2325"/>
                <count group_id="O2" value="2447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.713" spread="0.011"/>
                    <measurement group_id="O2" value="2.875" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.161</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.130</ci_lower_limit>
            <ci_upper_limit>0.192</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 42</title>
        <time_frame>Month 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 42</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2340"/>
                <count group_id="O2" value="2467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.073" spread="0.011"/>
                    <measurement group_id="O2" value="3.100" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0809</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.027</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.003</ci_lower_limit>
            <ci_upper_limit>0.057</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 48</title>
        <time_frame>Month 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Pre-bronchodilator Slow Vital Capacity (SVC) at Month 48</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2325"/>
                <count group_id="O2" value="2447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.696" spread="0.012"/>
                    <measurement group_id="O2" value="2.846" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.150</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.119</ci_lower_limit>
            <ci_upper_limit>0.182</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 48</title>
        <time_frame>Month 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Post-bronchodilator Slow Vital Capacity (SVC) at Month 48</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2340"/>
                <count group_id="O2" value="2467"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.041" spread="0.011"/>
                    <measurement group_id="O2" value="3.067" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0915</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.026</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.004</ci_lower_limit>
            <ci_upper_limit>0.057</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 6</title>
        <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 6</title>
          <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2337"/>
                <count group_id="O2" value="2478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.289" spread="0.240"/>
                    <measurement group_id="O2" value="39.409" spread="0.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.880</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.535</ci_lower_limit>
            <ci_upper_limit>-2.226</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 12</title>
        <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
        <time_frame>Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 12</title>
          <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2337"/>
                <count group_id="O2" value="2478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.501" spread="0.253"/>
                    <measurement group_id="O2" value="39.730" spread="0.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.771</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.461</ci_lower_limit>
            <ci_upper_limit>-2.081</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 18</title>
        <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
        <time_frame>Month 18</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 18</title>
          <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2337"/>
                <count group_id="O2" value="2478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.067" spread="0.278"/>
                    <measurement group_id="O2" value="40.474" spread="0.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.593</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.352</ci_lower_limit>
            <ci_upper_limit>-1.834</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 24</title>
        <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
        <time_frame>Month 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 24</title>
          <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2337"/>
                <count group_id="O2" value="2478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.562" spread="0.297"/>
                    <measurement group_id="O2" value="41.178" spread="0.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.384</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.191</ci_lower_limit>
            <ci_upper_limit>-1.576</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 30</title>
        <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
        <time_frame>Month 30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 30</title>
          <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2337"/>
                <count group_id="O2" value="2478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.342" spread="0.315"/>
                    <measurement group_id="O2" value="41.919" spread="0.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.423</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.277</ci_lower_limit>
            <ci_upper_limit>-1.569</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 36</title>
        <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
        <time_frame>Month 36</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 36</title>
          <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2337"/>
                <count group_id="O2" value="2478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.280" spread="0.326"/>
                    <measurement group_id="O2" value="41.935" spread="0.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.345</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.229</ci_lower_limit>
            <ci_upper_limit>-2.462</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 42</title>
        <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
        <time_frame>Month 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 42</title>
          <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2337"/>
                <count group_id="O2" value="2478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.722" spread="0.342"/>
                    <measurement group_id="O2" value="42.905" spread="0.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.818</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.742</ci_lower_limit>
            <ci_upper_limit>-1.894</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 48</title>
        <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
        <time_frame>Month 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated St George's Respiratory Questionnaire (SGRQ) Total Score at Month 48</title>
          <description>SGRQ total score summarizes the impact of COPD on overall patient's health status.
Total scores are expressed as a percentage of overall impairment where 100 represents worst possible health status and 0 indicates best possible health status.
The scale is continuous.
Rate of decline shows the yearly change of SGRQ total score.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2337"/>
                <count group_id="O2" value="2478"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.968" spread="0.357"/>
                    <measurement group_id="O2" value="43.665" spread="0.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANOVA</method>
            <method_desc>Repeated measures ANOVA</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.303</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.266</ci_lower_limit>
            <ci_upper_limit>-1.340</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Participants With All Cause Death and Time to Event Analysis (On-treatment)</title>
        <description>On-treatment defined as day 1 to completion of double blinded treatment plus 30 days</description>
        <time_frame>Day 1 to completion of double blinded treatment plus 30 days between Day 1 and 4 years plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Participants With All Cause Death and Time to Event Analysis (On-treatment)</title>
          <description>On-treatment defined as day 1 to completion of double blinded treatment plus 30 days</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with on-treatment death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402"/>
                    <measurement group_id="O2" value="374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage patients with on-treatment death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4"/>
                    <measurement group_id="O2" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0242</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Cox regression with treatment; hazard ratio shown as tiotropium bromide vs. placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number and Percentage of Participants With All Cause Death (Including Vital Status Follow-up, Cutoff at 1440 Days)</title>
        <time_frame>Day 1 to day 1440</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Participants With All Cause Death (Including Vital Status Follow-up, Cutoff at 1440 Days)</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients died from day 1 to day 1440</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="491"/>
                    <measurement group_id="O2" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of patients died from day 1 to day 1440</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard ratio of all cause mortality vital status was information followed-up after discontinuation; vital status information up to 1440 days after the start of treatment was used</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0339</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>Cox regression; cut-off at 4 years ; vital status form intended at 4 years; hazard ratio shown as tio vs. placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Participants With All Cause Death (Including Vital Status Follow-up, Cutoff at 1470 Days)</title>
        <description>All cause mortality vital status information was followed-up after discontinuation; vital status information up to 1470 days after the start of treatment was used.</description>
        <time_frame>Day 1 to day 1470</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Participants With All Cause Death (Including Vital Status Follow-up, Cutoff at 1470 Days)</title>
          <description>All cause mortality vital status information was followed-up after discontinuation; vital status information up to 1470 days after the start of treatment was used.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients died from day 1 to day 1470</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="495"/>
                    <measurement group_id="O2" value="446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of patients died from day 1 to day 1470</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                    <measurement group_id="O2" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0859</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>Cox regression; cut-off at 4 years plus 30 days; vital status form intended at 4 years; hazard ratio shown as tio vs. placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Participants With Lower Respiratory Death (On-treatment; Adjudicated Primary Cause)</title>
        <description>The primary cause of death was adjudicated by an external committee prior to unblinding; on-treatment defined as day 1 to completion of double blinded treatment plus 30 days</description>
        <time_frame>Day 1 to completion of double blinded treatment plus 30 days between Day 1 and 4 years plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Participants With Lower Respiratory Death (On-treatment; Adjudicated Primary Cause)</title>
          <description>The primary cause of death was adjudicated by an external committee prior to unblinding; on-treatment defined as day 1 to completion of double blinded treatment plus 30 days</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with lower respiratory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of patients with lower respiratory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1936</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>Cox regression with treatment; hazard ratio shown as tiotropium bromide vs. placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Participants With a Lower Respiratory Death (Adjudicated; Including Vital Status Follow-up, Cutoff at 1470 Days)</title>
        <description>The primary cause of death was adjudicated by an external committee prior to unblinding; vital status was information followed-up after discontinuation; vital status information up to 1470 days after the start of treatment was used</description>
        <time_frame>Day 1 to day 1470</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Participants With a Lower Respiratory Death (Adjudicated; Including Vital Status Follow-up, Cutoff at 1470 Days)</title>
          <description>The primary cause of death was adjudicated by an external committee prior to unblinding; vital status was information followed-up after discontinuation; vital status information up to 1470 days after the start of treatment was used</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with lower respiratory death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage patients with lower respiratory death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2377</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>Cox regression; cut-off at 4 years plus 30 days; vital status form intended at 4 years; hazard ratio shown as tiotropium bromide vs. placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence Rate of Serious Adverse Event (System Organ Class = Cardiac Disorders)</title>
        <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
        <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Serious Adverse Event (System Organ Class = Cardiac Disorders)</title>
          <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
          <units>Number of patients with event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="350"/>
                    <measurement group_id="O2" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence rate (number of events/100 patient year)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21"/>
                    <measurement group_id="O2" value="3.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0290</p_value>
            <method>Z-test</method>
            <method_desc>incidence rate = number of patients with event/ time at risk</method_desc>
            <param_type>Rate ratio of incidence rates</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Rate ratio of incidence rates (tiotropium/placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence Rate of Serious Adverse Event (Preferred Term = Angina)</title>
        <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
        <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Serious Adverse Event (Preferred Term = Angina)</title>
          <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
          <units>Number of patients with event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence rate (number events/100-patient years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36"/>
                    <measurement group_id="O2" value="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1158</p_value>
            <method>Z-test</method>
            <param_type>Rate ratio of incidence rates</param_type>
            <param_value>1.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>2.26</ci_upper_limit>
            <estimate_desc>Rate ratio of incidence rates (tiotropium/placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence Rate of Serious Adverse Event (Preferred Term = Atrial Fibrillation)</title>
        <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
        <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Serious Adverse Event (Preferred Term = Atrial Fibrillation)</title>
          <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
          <units>Number of patients with event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence rate (number events/100-patient years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77"/>
                    <measurement group_id="O2" value="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7725</p_value>
            <method>Z-test</method>
            <param_type>Rate ratio of incidence rates</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
            <estimate_desc>Rate ratio of incidence rates (tiotropium/placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence Rate of Serious Adverse Event (Preferred Term = Cardiac Failure)</title>
        <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
        <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Serious Adverse Event (Preferred Term = Cardiac Failure)</title>
          <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
          <units>Number of patients with event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence rate (number events/100-patient years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48"/>
                    <measurement group_id="O2" value="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2666</p_value>
            <method>Z-test</method>
            <param_type>Rate ratio of incidence rates</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
            <estimate_desc>Rate ratio of incidence rates (tiotropium/placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence Rate of Serious Adverse Event (Preferred Term = Cardiac Failure Congestive)</title>
        <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
        <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Serious Adverse Event (Preferred Term = Cardiac Failure Congestive)</title>
          <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
          <units>Number of patients with event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence rate (number events/100-patient years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48"/>
                    <measurement group_id="O2" value="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0337</p_value>
            <method>Z-test</method>
            <param_type>Rate ratio of incidence rates</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
            <estimate_desc>Rate ratio of incidence rates (tiotropium/placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence Rate of Serious Adverse Event (Preferred Term = Coronary Artery Disease)</title>
        <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
        <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Serious Adverse Event (Preferred Term = Coronary Artery Disease)</title>
          <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
          <units>Number of patients with event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence rate (number events/100-patient years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37"/>
                    <measurement group_id="O2" value="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0537</p_value>
            <method>Z-test</method>
            <param_type>Rate ratio of incidence rates</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>Rate ratio of incidence rates (tiotropium/placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence Rate of Serious Adverse Event (Preferred Term = Myocardial Infarction)</title>
        <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
        <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Serious Adverse Event (Preferred Term = Myocardial Infarction)</title>
          <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
          <units>Number of patients with event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence rate (number events/100-patient years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97"/>
                    <measurement group_id="O2" value="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0403</p_value>
            <method>Z-test</method>
            <param_type>Rate ratio of incidence rates</param_type>
            <param_value>0.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>Rate ratio of incidence rates (tiotropium/placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence Rate of Serious Adverse Event (System Organ Class = Lower Respiratory System Disorders)</title>
        <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
        <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Serious Adverse Event (System Organ Class = Lower Respiratory System Disorders)</title>
          <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
          <units>Number of patients with event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="985"/>
                    <measurement group_id="O2" value="911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence rate (number events/100-patient years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.47"/>
                    <measurement group_id="O2" value="11.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Z-test</method>
            <param_type>Rate ratio of incidence rates</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
            <estimate_desc>Rate ratio of incidence rates (tiotropium/placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence Rate of Serious Adverse Event (Preferred Term = Bronchitis)</title>
        <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
        <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Serious Adverse Event (Preferred Term = Bronchitis)</title>
          <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
          <units>Number of patients with event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence rate (number events/100-patient years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31"/>
                    <measurement group_id="O2" value="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4789</p_value>
            <method>Z-test</method>
            <param_type>Rate ratio of incidence rates</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
            <estimate_desc>Rate ratio of incidence rates (tiotropium/placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence Rate of Serious Adverse Event (Preferred Term = Chronic Obstructive Pulmonary Disease (COPD) Exacerbation)</title>
        <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
        <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Serious Adverse Event (Preferred Term = Chronic Obstructive Pulmonary Disease (COPD) Exacerbation)</title>
          <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
          <units>Number of patients with event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="742"/>
                    <measurement group_id="O2" value="688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence rate (number events/100-patient years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.70"/>
                    <measurement group_id="O2" value="8.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>Z-test</method>
            <param_type>Rate ratio of incidence rates</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
            <estimate_desc>Rate ratio of incidence rates (tiotropium/placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence Rate of Serious Adverse Event (Preferred Term = Dyspnoea)</title>
        <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
        <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Serious Adverse Event (Preferred Term = Dyspnoea)</title>
          <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
          <units>Number of patients with event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence rate (number events/100-patient years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62"/>
                    <measurement group_id="O2" value="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0236</p_value>
            <method>Z-test</method>
            <param_type>Rate ratio of incidence rates</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
            <estimate_desc>Rate ratio of incidence rates (tiotropium/placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence Rate of Serious Adverse Event (Preferred Term = Pneumonia)</title>
        <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
        <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Serious Adverse Event (Preferred Term = Pneumonia)</title>
          <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
          <units>Number of patients with event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290"/>
                    <measurement group_id="O2" value="296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence rate (number events/100-patient years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.46"/>
                    <measurement group_id="O2" value="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5064</p_value>
            <method>Z-test</method>
            <param_type>Rate ratio of incidence rates</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>Rate ratio of incidence rates (tiotropium/placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence Rate of Serious Adverse Event (Preferred Term = Respiratory Failure)</title>
        <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
        <time_frame>Day 1 to completion of double blinded treatment plus 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
            <description>Once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate of Serious Adverse Event (Preferred Term = Respiratory Failure)</title>
          <description>Descriptive statistics show the number of patients with event, central tendency shows incidence rate. Incidence rate calculated as number of patients with event divided by at-risk years * 100.</description>
          <units>Number of patients with event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3006"/>
                <count group_id="O2" value="2986"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients with event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence rate (number events/100-patient years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31"/>
                    <measurement group_id="O2" value="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0104</p_value>
            <method>Z-test</method>
            <param_type>Rate ratio of incidence rates</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
            <estimate_desc>Rate ratio of incidence rates (tiotropium/placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 30 days after last drug administration</time_frame>
      <desc>The Dictionary used to report the adverse events is Sponsor-defined based on the MedDRA version 11.0</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Once daily</description>
        </group>
        <group group_id="E2">
          <title>Tiotropium Bromide Inhalation Capsules 18 mcg</title>
          <description>Once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1509"/>
                <counts group_id="E2" subjects_affected="1540"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypocoagulable state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Splenic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Splenic lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Splenic vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated idioventricular rhythm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Acute right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiac aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cor pulmonale acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cor pulmonale chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Coronary artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypertensive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pericardial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Torsade de pointes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ventricular hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomatous polyposis coli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Congenital myopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dolichocolon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastrointestinal arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Neurofibromatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Otosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Adrenal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Diabetes insipidus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Thyroid disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Iridocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Duodenal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Femoral hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastric varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastric volvulus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastrooesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ileitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Internal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intestinal angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intestinal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intestinal mucosal hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Loose tooth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Malabsorption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Mouth cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Oesophagitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pancreatic duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Parotid lipomatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Polyp colorectal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Rectal discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Salivary gland mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cyst rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Multi-organ disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Multimorbidity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Perforated ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cholelithiasis obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Chronic hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Corynebacterium infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cystitis escherichia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dermo-hypodermitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Fungaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Escherichia coli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Haemorrhoid infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Herpes zoster infection neurological</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hydrocele male infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intertrigo candida</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Joint abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Meningitis listeria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Meningococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Mycobacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Nosocomial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Perianal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Periodontal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Peritoneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Peritoneal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Post procedural pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Toxic shock syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Anastomotic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bladder injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Burn of internal organs</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bursa injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker malfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Caustic injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Decerebration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Delayed recovery from anaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Foreign body trauma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastrointestinal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ilium fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Incision site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Internal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Operative haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pacemaker complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pancreatic injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Post gastric surgery syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Post procedural fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pubic rami fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Shunt thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Stent occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Stent-graft endoleak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Synovial rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ulnar nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Urinary tract injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Vaccination complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Vascular bypass dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Vena cava injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Physical examination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Urine calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bone cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Facet joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Fracture nonunion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intervertebral disc displacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Loose body in joint</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metatarsalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Myalgia intercostal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Myopathy steroid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Polymyositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acoustic neuroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Adrenal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Basosquamous carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Basosquamous carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Benign colonic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bladder adenocarcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bladder cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bladder cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bone cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bone neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the small bowel</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Carcinoma in situ of bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cerebellar tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Colon cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastric adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastric cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastric cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastric cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastric cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Head and neck cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Large intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lentigo maligna stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lip neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Liposarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lymph node cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Malignant melanoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of renal pelvis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Malignant palate neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Malignant pericardial neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Malignant respiratory tract neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Malignant urinary tract neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Mesothelioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metastases to adrenals</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metastases to breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metastases to skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metastases to soft tissue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metastatic carcinoma of the bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Mycosis fungoides</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Neoplasm recurrence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Oesophageal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Oral neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Penis carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Penis carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Rectal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Rectal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Renal cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Retroperitoneal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Small cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Small intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Small intestine carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Tumour invasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ureteric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Anoxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cerebellar syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cervical cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Chronic inflammatory demyelinating polyradiculoneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Coma hepatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Complex regional pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Diabetic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypercapnic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypoxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intracranial haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intracranial hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Locked-in syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Paresis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Quadriparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Radicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Radiculitis cervical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Spinal cord infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Spinal cord ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dysthymic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Mental disorder due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Neurosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Nicotine dependence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Tobacco withdrawal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bladder diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Renal aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Urethral disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Calculus prostatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Epididymal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Organic erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Prostatic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Scrotal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Uterine cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Uterine enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Actinomycotic pulmonary infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Alveolitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Aspergilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="742" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="688" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cryptogenic organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lung injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Middle lobe syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="290" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="296" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pseudomonas bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pulmonary bulla</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Respiratory fume inhalation disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Respiratory tract haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Benign lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bronchial neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bronchogenic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Large cell carcinoma of the respir. tract stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Malignant mediastinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Mediastinum neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Metastatic bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pharyngeal cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pulmonary hilum mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer extensive stage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer limited stage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Throat cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Tracheal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Laryngeal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Laryngospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Oropharyngeal swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pharyngeal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pharyngeal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pharyngeal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pharyngoesophageal diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Sinus polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Tracheal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Tracheostomy malfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Parapsoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Skin haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Alcohol use</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Social problem</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Social stay hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Victim of homicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Adhesiolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Alcohol detoxification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Appendicectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bladder operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker battery replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Catheter placement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Colectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Finger amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tube insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hip surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ileostomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intervertebral disc operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Joint arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Nasal polypectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Oxygen supplementation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Rehabilitation therapy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Removal of internal fixation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Respiratory therapy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Shoulder operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Umbilical hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Aortic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Aortic occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Aortic rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Aortic thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Arterial insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Arteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Bleeding varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Jugular vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Superior vena caval occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Varicose ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Vascular shunt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Venous stasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2622"/>
                <counts group_id="E2" subjects_affected="2643"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mouth dry</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="173" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="207" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="1743" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="1706" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="212" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="236" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="404" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="338" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="155" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="323" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="373" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="2986"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="282" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="285" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="273" subjects_at_risk="3006"/>
                <counts group_id="E2" subjects_affected="265" subjects_at_risk="2986"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Tio patients had significantly longer drug exposure,thus had increased chance of AE.Simple frequencies are biased for AE comparisons;exposure-adjusted incidence rates (IR) should be used. IR for serious AE(&gt;1% patients) are in Outcome Measures.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Pharmaceuticals</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

